Skip to main content
. 2017 Jul 27;8(56):95135–95151. doi: 10.18632/oncotarget.19619

Figure 1. High CMKLR1 and GPR1 expression predicts poor survival in neuroblastoma patients.

Figure 1

Expression data was analyzed using the R2 database http://r2.amc.nl. Kaplan-Meier survival estimates were used to evaluate the prognostic value of CMKLR1 (A, B) and GPR1 (D, E) expression in two patient data sets (A and D: Versteeg n=88; B and E: Seeger n=102). The Kaplan-Meier scanning tool was used to determine the CMKLR1 and GPR1 mRNA expression in neuroblastoma. All expression data were scanned to find the most optimal cut-off between high and low gene expression and the log-rank test that gave the lowest p-value was calculated to search for significant differences between tumor samples expressing high and low CMKLR1 and GPR1 mRNA levels, respectively. The expression of CMKLR1 (C) and GPR1 (F) was compared between neural crest (Etchevers n=5), benign neurofibroma (Miller n=86) and 4 neuroblastoma cohorts (cohort 1: Versteeg n=88, cohort 2: Delattre n=64, cohort 3: Hiyama n=51, cohort 4: Lastowska n=30).